

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32721A
APPLICATION NO.
10/530,618
APPLICANT
HOUGHTON ET AL.
FILING DATE
FEBRUARY 23, 2006

Group

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|---------------------|----|-----------------|------|------|-------|----------|-------------|
| | AA | | | | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| | AF | | | | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| | AL | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRANSLATION | |
|--|----|-----------------|------|--------|-------|----------|--------------------------|--------------------------|
| | | | | | | | YES | NO |
| | AM | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AN | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AO | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AP | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AQ | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

| | | |
|--------|----|---|
| /B.P./ | AR | Houghton et al., "Imatinib mesylate (STI571, Gleevec) is a potent inhibitor of BCRP (ABCG2) and reverses topotecan resistance in vitro," Abstract No. 1959, Proceedings of the American Association for Cancer Research, Vol. 44, March (2003) Abstract |
| /B.P./ | AS | Litman et al., "From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance," Cellular and Molecular Life Sciences, Vol. 58, pp. 931-959 (2001) |
| /B.P./ | AT | Lage et al., "Effect of the breast-cancer resistance protein on atypical multidrug resistance," The Lancet Oncology, Vol. 1, pp. 169-75 (2000) |

EXAMINER

/Benjamin Packard/

DATE CONSIDERED

01/10/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
ON/4-32721A
APPLICATION NO.
10/530,618
APPLICANT
HOUGHTON ET AL.
FILING DATE
FEBRUARY 23, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

| | | |
|--------|----|---|
| /B.P./ | DA | Ross D.D., "Novel mechanisms of drug resistance in leukemia," Leukemia, Vol. 14, pp. 467-473 (2000) |
| /B.P./ | DB | Wu et al., "Drug-resistant proteins in breast cancer: recent progress in multidrug resistance," Ai Zheng, Vol. 22(4), pp. 441-4 (2003) Abstract |
| /B.P./ | DC | Tan et al., "Multidrug resistance transporters and modulation," Current Opinion in Oncology 2000, Vol. 12, pp. 450-458 (2000) |
| /B.P./ | DD | Kawabata et al., "Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells," Biochemical and Biophysical Research Communications, Vol. 280, pp. 1216-1223 (2001) |
| /B.P./ | DE | Erllichman et al., "The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux," Cancer Research, Vol. 61, pp. 739-748 (2001) |
| /B.P./ | DF | Sparreboom et al., "Pharmacogenomics of ABC transporters and its role in cancer chemotherapy," Drug Resistance Updates 6, pp. 71-84 (2003) |
| | DG | |
| | DH | |
| | DI | |
| | DJ | |
| | DK | |
| | DL | |
| | DM | |
| | DN | |

EXAMINER

/Benjamin Packard/

DATE CONSIDERED

01/10/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.